Inductive No-synthase activity and citlulline content in blood serum as markers of immuno-inflammatory activation and oxidative stress under chronic heart failure

  • Received 15.12.2021

  • Revised 18.01.2022

  • Accepted 23.02.2022



  • 1,206 Views

  • Retrieved from Volume 3, No. 4, 2021

  • Pages 46-52

Summary. Nitric oxide (NO) is a powerful endothelium-relaxing factor that causes vascular smooth muscle relaxation, inhibits their proliferation, and participates in the regulation of systemic and pulmonary vascular resistance, platelet aggregation processes, blood clotting and more. The aim of the study – to investigate iNOS activity, immunoinflammatory response and oxidative stress intensity in chronic heart failure (CHF). Materials and Methods. The study was performed on the basis of the Department of Heart Failure of the Institute of Cardiology named after Acad. M. D. Strazhesk, National Academy of Medical Sciences of Ukraine. 120 patients with CHF of both sexes aged (63±3.4) were examined, 76 of them with coronary heart disease (CHD) and 44 with hypertension. The criteria for involving patients in the study were: 1) CHF class II-IV according to NYHA with LV HF (ejection fraction (EF) of LV ≤45 %); 2) age ≤75 years. Exclusion criteria for the study were: 1) age> 75 years;  2) LV EF ≥45% according to echocardiographic examination; 3) CHF as a consequence of valve defects, inflammatory heart disease; 4) hypertrophic and restrictive cardiomyopathy; 5) acute coronary heart disease; 6) suffered a stroke or transient ischemic attack <6 months old; 7) oncological diseases; 8) acute infectious diseases. Statistical processing of the results was performed using the application package Statistica for Windows. Significance of diffe­rences between quantitative traits with normal distribution was performed using the odd Student's t-test. When comparing the two independent groups, the Mann-Whitney test (U) and the Wilcoxon test (W) were used for the two independent groups if the distribution of the indicator did not correspond to normal. The difference was considered statistically significant at p <0.05. Results. We examined 120 patients with CHF of both sexes aged (63±3.4), including 76 with coronary heart disease and 44 with arterial hypertension. Studies have shown that the formation of oxidative stress is observed in CHF, as indicated by an increase in the content of oxidation products of lipids, proteins in serum and lipoprotein fractions. Intensification of free radical oxidative processes occurs against the background of significant inhibition of the activity of antioxidant defense systems – catalase and superoxide dismutase. At the same time, there is a decrease in the level of reduced glutathione and paraoxonase-1 activity. The presence of immunoinflammatory activation is indicated by a doubling of serum ceruloplasmin and proinflammatory cytokines IL-6 and TNF-α. The results of the NBT-test with immunocompetent cells indicate an increase in phagocytic activity of cells in a systemic inflammatory response. The doubling of the activity of the enzyme myeloperoxidase in the blood of the examined patients also serves as evidence of the activity of neutrophils and monocytes in the systemic inflammatory response. These changes in immuno-biochemical parameters were accompanied by an increase in the total content of citrulline in the serum by two or more times. This may be the result of excessive activation of the inducible isoform of NO-synthase under conditions of inflammatory reaction and under the influence of elevated levels of proinflammatory cytokines. The activity of the iNOS isoform under these conditions was increased threefold. Conclusions. In the relationship between systemic immune activation and the intensity of oxidative stress, activation of iNOS in blood cells and the cardiovascular system can be considered an important link. Therefore, iNOS acti­vity and increased circulating levels of citrulline can be considered markers of immune activation and oxidative stress, which cause the progression of underlying cardiovascular disease and CHF

chronic heart failure, iNO-synthase, citrulline

https://doi.org/10.11603/bmbr.2706-6290.2021.4.12492

[1] Moibenko OO, Sahach VF, Tkachenko MM, Korkushko OV, Bezrukov VV, Kulchytskyi OK, Stefanov OV, Soloviov AI, Mala LT, Frolkis VV. [Fundamental mechanisms of action of nitric oxide on the cardiovascular system as a basis for pathogenetic  treatment  of  its  diseases].  Fiziolohichnyi zhurnal.  2004;50(1):  11-30. Available  from:  https://fz.kiev.ua/index.php?abs=344

[2] Gladwin MT, Raat NJH, Shiva S, Dezfulian C, Hogg N, Kim-Shapiro DB, et al. Nitrite as a vascular endocrine ni-tric oxide reservoir that contributes to hypoxic signaling, cytoprotection, and vasodilation. Am J Physiol Circ Physiol. 2006;291(5):  H2026-35. Available  at:  https://www.physiol-ogy.org/doi/10.1152/ajpheart.00407.2006

[3] Chatterjee A,  Catravas  JD.  Endothelial  nitric  oxide (NO) and its pathophysiologic regulation. Vascul Pharma-col. 2008;49(4-6): 134-40. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1537189108000815

[4] Bahri S, Zerrouk N, Aussel C, Moinard C, Crenn P, Curis E, et al. Citrulline: From metabolism to therapeutic use. Nutrition. 2013;29(3): 479-84. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0899900712002584

[5] Moinard  C,  Cynober  L.  Citrulline: A  new  player  in the control of nitrogen homeostasis. J Nutr. 2007;137(6): 1621S-5S.  Available  from:  https://academic.oup.com/jn/article/137/6/1621S/4664929

[6] Stuehr DJ. Enzymes of the L-Arginine to nitric oxide pathway. J Nutr. 2004;134(10): 2748S-51S. Available from: https://academic.oup.com/jn/article/134/10/2748S/4688471

[7] McSorley SI. Nitric oxide pathway. В: Encyclopedia of immunology. PI. Devis. N.Y.Academic press; 2004.

[8] Meirelles de LR, Resende A de C, Matsuura C, Sal-gado Â, Pereira NR, Cascarelli PG, et al. Platelet activation, oxidative stress and overexpression of inducible nitric oxide synthase in moderate heart failure. Clin Exp Pharma-col Physiol. 2011;38(10): 705-10. Available from: https://on-linelibrary.wiley.com/doi/10.1111/j.1440-1681.2011.05580.x

[9] Rath  M,  Müller  I,  Kropf  P,  Closs  EI,  Munder  M. Metabolism  via  arginase  or  nitric  oxide  synthase:  Two competing  arginine  pathways  in  macrophages.  Front Immunol.  2014;5. Available  from:  http://journal.frontiersin.org/article/10.3389/fimmu.2014.00532/abstract

[10] Stalnaya ID. Method for determination of diene con-jugation of unsaturated higher fatty acids. [Метод определения  диеновой  конъюгации  ненасыщенных  высших жирных кислот] Moscow: Meditsina; 1977. Russian.

[11] Stalnaya ID. Garishvili TG. Method for the determi-nation  of  malondialdehyde  using  thiobarbituric  acid. [Метод определения малонового диальдегида с помощью тиобарбитуровой кислоты] Orekhovich VN. ed. Moscow: Meditsina. Russian.

[12] Dubinina EE, Burmistrov SO, Khodov DA, Porotov IG.  [Oxidative  modification  of  human  serum  proteins.  A method  of  determining  it].  Vopr  med  khim.  1995;41(1): 24-6.   Available   from:   http://www.ncbi.nlm.nih.gov/pubmed/7771084

[13] A method for diagnosing progressive atherosclerosis: Pat. 30972 Ukraine: G01N33 / 48 / Evstratova IN, Mkhitaryan LS,  Orlova  NM,  Kazimirko  EI,  Fedun  NM,  Drobotko  TF. No. 30972A; stated 25.06.1998; publ. 15.12.2000, Bull No. 7.

[14] Korolyuk MA, Ivanova LI, Majorova IG, Tokarev VE [Method  for  determining  catalase  activity].  Laboratornoe delo. 1988;(1): 16-9. Russian.

[15] Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247(10): 3170-5. Available  from:  https://linkinghub.elsevier.com/retrieve/pii/S0021925819452289

[16] Manolescu  BN,  Berteanu  M,  Cintezã  D.  Effect  of the nutritional supplement ALAnerv® on the serum PON1 activity in post-acute stroke patients. Pharmacol Reports. 2013;65(3):  743-50.  Available  from:  https://linkinghub.elsevier.com/retrieve/pii/S1734114013710545

[17] Docenko OI. [Functioning of the erythrocyte gluta-thione system under conditions of oxidative stress]. Vestnik Donetsk natі univer. 2009;2: 254-9. Russian.

[18] Kamyshnikov  VS.  Handbook  of  clinical  and  bio-chemical laboratory diagnostics in 2 vol. [Справочник по клинико-биохимической лабораторной диагностике. – в 2 т.] Minsk: Belarus; 2000. Russian.

[19] Gorudko IV, Kostevich, VA, Sokolov AV, Buko IV, Kon-stantinova EE, Capaeva NL, Mironova EV et al. [Increased activity of myeloperoxidase - a risk factor for coronary heart disease in patients with diabetes mellitus]. Biomeditsinska-ya himiya. 2012;58(4): 485-4. Available from: http://pbmc.ibmc.msk.ru/pdf/PBMC-2012-58-4-475. Russian.

[20] A method of determining the functional state of the inducible NO-synthase system in patients with cardiovascu-lar pathology: UA Pat. u201011861 Ukraine: IPC (2011.01) G01N 33/00. Mkhitaryan LS, Evstratova IN, Yakushko LV, Lipkan NG, Gavrylenko TI. No. 57878; stated 06.10.2010; publ. 10.03.2011, Bul. No. 5. Ukrainian.

[21] Snell FD, Snell ST. Colorimetric method of analysis. New York: Van Nostard; 2013.

[22] Chistyakov DA, Melnichenko AA, Orekhov AN. [Car-diovascular diseases associated with paraoxonase and ath-erosclerosis]. Biohimiya. 2017;132: 19-27. Russian.

[23] Giannitsi  S,  Maria  B,  Bechlioulis A,  Naka  K.  En-dothelial dysfunction and heart failure: A review of the ex-isting  bibliography  with  emphasis  on  flow  mediated  dila-tion.  JRSM  Cardiovasc  Dis.  2019;8:  204800401984304. Available from: http://journals.sagepub.com/doi/10.1177/2048004019843047

[24] Aimo A, Castiglione V, Borrelli C, Saccaro LF, Fran-zini  M,  Masi  S,  et  al.  Oxidative  stress  and  inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020;27(5): 494-510.  Available  from:  https://academic.oup.com/eurjpc/ar-ticle/27/5/494-510/5924888